China Meheco(SH:600056) 第一财经·2025-12-27 08:23Core Viewpoint - The investigation of Gao Yuwen, former chairman of China National Pharmaceutical Group Co., Ltd., highlights ongoing corruption issues within the company, which has seen multiple executives investigated in recent years, coinciding with declining financial performance [4][6]. Group 1: Company Investigation - Gao Yuwen is under investigation for serious violations of discipline and law, conducted by the Central Commission for Discipline Inspection and the Tianjin Municipal Supervisory Committee [4]. - Since 2024, at least 11 executives or former executives from China National Pharmaceutical have been investigated for corruption [6]. - The company has a history dating back to 1983 and is now the sole pharmaceutical and medical device platform under the General Technology Group [5]. Group 2: Financial Performance - In 2024, the company reported a revenue of 34.148 billion yuan, a year-on-year decrease of 12.04%, and a net profit of 535 million yuan, down 48.91% [8]. - For the first half of 2025, revenue was 17.076 billion yuan, a decline of 6.71%, with a net profit of 294 million yuan, down 16.19% [8]. - By the third quarter of 2025, the net profit attributable to shareholders was 477 million yuan, reflecting a year-on-year decrease of 4.64% [9].